LORISTA H 50MG/12,5MG Potahovaná tableta República Tcheca - tcheco - SUKL (Státní ústav pro kontrolu léčiv)

lorista h 50mg/12,5mg potahovaná tableta

krka, d.d., novo mesto, novo mesto array - 14167 draselnÁ sŮl losartanu; 728 hydrochlorothiazid - potahovaná tableta - 50mg/12,5mg - losartan a diuretika

VALTRICOM 10MG/160MG/12,5MG Potahovaná tableta República Tcheca - tcheco - SUKL (Státní ústav pro kontrolu léčiv)

valtricom 10mg/160mg/12,5mg potahovaná tableta

krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan; 728 hydrochlorothiazid - potahovaná tableta - 10mg/160mg/12,5mg - valsartan, amlodipin a hydrochlorothiazid

VALTRICOM 10MG/160MG/25MG Potahovaná tableta República Tcheca - tcheco - SUKL (Státní ústav pro kontrolu léčiv)

valtricom 10mg/160mg/25mg potahovaná tableta

krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan; 728 hydrochlorothiazid - potahovaná tableta - 10mg/160mg/25mg - valsartan, amlodipin a hydrochlorothiazid

VALTRICOM 10MG/320MG/25MG Potahovaná tableta República Tcheca - tcheco - SUKL (Státní ústav pro kontrolu léčiv)

valtricom 10mg/320mg/25mg potahovaná tableta

krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan; 728 hydrochlorothiazid - potahovaná tableta - 10mg/320mg/25mg - valsartan, amlodipin a hydrochlorothiazid

VALTRICOM 5MG/160MG/12,5MG Potahovaná tableta República Tcheca - tcheco - SUKL (Státní ústav pro kontrolu léčiv)

valtricom 5mg/160mg/12,5mg potahovaná tableta

krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan; 728 hydrochlorothiazid - potahovaná tableta - 5mg/160mg/12,5mg - valsartan, amlodipin a hydrochlorothiazid

VALTRICOM 5MG/160MG/25MG Potahovaná tableta República Tcheca - tcheco - SUKL (Státní ústav pro kontrolu léčiv)

valtricom 5mg/160mg/25mg potahovaná tableta

krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan; 728 hydrochlorothiazid - potahovaná tableta - 5mg/160mg/25mg - valsartan, amlodipin a hydrochlorothiazid

Galvus União Europeia - tcheco - EMA (European Medicines Agency)

galvus

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - léky užívané při diabetu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Jalra União Europeia - tcheco - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pro dostupné údaje o různých kombinacích).

Lyxumia União Europeia - tcheco - EMA (European Medicines Agency)

lyxumia

sanofi winthrop industrie - lixisenatid - diabetes mellitus, typ 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Xiliarx União Europeia - tcheco - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - léky užívané při diabetu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pro dostupné údaje o různých kombinacích).